CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
Alteplase Injectable Productdrug
Likely dose
Alteplase Injectable Product 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06667882
NCT06667882N/ACompleted
CompareCT.gov

Safe Delivery of Thrombolytic Treatment for Pulmonary Embolism Using ClotPro® Viscoelastic Tests

Semmelweis University·interventional·Posted Oct 31, 2024·Updated Oct 31, 2024

In Brief

A clinical study evaluating Alteplase Injectable Product for Pulmonary Embolism Subacute Massive and 2 related conditions. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The aim of this work was to reduce the bleeding risk during thrombolysis using the viscoelastic blood coagulation tests.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Embolism Subacute Massive, Complication of Treatment, Fibrinolysis; Hemorrhage
CountriesHungary
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedOct 31, 2024
Enrollment StartDec 17, 2021
Primary CompletionOct 24, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 1.7 years ago

Interventions

Alteplase Injectable Productdrug

The 2019 ESC guideline for the diagnosis and management of acute pulmonary embolism (PE) recommended thrombolytic therapy only in high-risk PE cases because of the bleeding risk. The most often used drug for thrombolysis is the rtPA and the recommended dose is 100 mg over two hours. According to the literature, the risk of major haemorrhage is 10-13% and fatal or intracranial bleeding is 1.7-3.6% among patients receiving thrombolysis.